Prometheus Biosciences Inc (RXDX) PT Raised to $142 at Credit Suisse, 'Taking Up Our Numbers to Reflect Strong Ph2 IBD Data'
Tweet Send to a Friend
Credit Suisse analyst Martin Auster raised the price target on Prometheus Biosciences Inc (NASDAQ: RXDX) to $142.00 (from $59.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
